P123 Increased SLE burden in patients of lower economic status

Autor: Alain Cornet, Jeanette Andersen, Zoe Karakikla

Publikováno v: Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)

Externí odkaz: https://doaj.org/article/f872abdb25ea469eb56bd44b2933abcf

22 The patient´s voice

Autor: Jeanette Andersen

Publikováno v: Lupus Science and Medicine, Vol 10, Iss Suppl 2 (2023)

Externí odkaz: https://doaj.org/article/214057a346744f25baf719e3e41c5018

What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts

Autor: Ralph Brinks, Guillermo Ruiz-Irastorza, Benjamin Terrier, László Czirják, Íñigo Rúa-Figueroa, Jose Maria Pego-Reigosa, Johanna Mucke, Gamal Chehab, Eric Morand, Luís Inês, Anne Voss, Jeanette Andersen, Mariele Gatto, Marta Alarcon-Riquelme, Matthew H Liang

Publikováno v: Lupus Science and Medicine, Vol 8, Iss 1 (2021)

Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythematosus (SLE), many clinical trials have failed in the past few years. The disappointing results have been at least partly be attributed to trial design

Externí odkaz: https://doaj.org/article/c3dc655a039746f8b3c145ec2bdcb520

Bioassay-Guided Fractionation Leads to the Detection of Cholic Acid Generated by the Rare Thalassomonas sp

Autor: Fazlin Pheiffer, Yannik Schneider, Espen Hansen, Jeanette Andersen, Johan Isaksson, Tobias Busche, Christian Rückert, Jörn Kalinowski, Leonardo Zyl, Marla Trindade

Publikováno v: Marine Drugs
Volume 21
Issue 1
Pages: 2

Bacterial symbionts of marine invertebrates are rich sources of novel, pharmaceutically relevant natural products that could become leads in combatting multidrug-resistant pathogens and treating disease. In this study, the bioactive potential of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1d2b052015f78a8aa374a5a4f5f4e10
https://hdl.handle.net/10037/28041

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

Autor: Ronald F van Vollenhoven, Zgjim Osmani, Jeanette Andersen, Wendy Zacouris-Verweij, Alain Cornet, Susan Frankel, Thijs J Schrama, Irene E. M. Bultink

Publikováno v: Lupus Science & Medicine
Lupus Science and Medicine, Vol 8, Iss 1 (2021)
Osmani, Z, Schrama, T J, Zacouris-Verweij, W, Andersen, J, Frankel, S, Bultink, I E M, Cornet, A & Van Vollenhoven, R F 2021, ' Hydroxychloroquine treatment in European patients with lupus erythematosus : Dosing, retinopathy screening and adherence ', Lupus Science and Medicine, vol. 8, no. 1, e000478 . https://doi.org/10.1136/lupus-2021-000478
Lupus Science and Medicine, 8(1):e000478. BMJ Publishing Group
Lupus science & medicine, 8(1):e000478. BMJ Publishing Group

BackgroundUse of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, ≥5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy. Advances in our understanding of HCQ r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f5ee15dbc72525b961502a1192842c7
https://pubmed.ncbi.nlm.nih.gov/33795484